DE602004005814D1 - PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOF - Google Patents
PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOFInfo
- Publication number
- DE602004005814D1 DE602004005814D1 DE602004005814T DE602004005814T DE602004005814D1 DE 602004005814 D1 DE602004005814 D1 DE 602004005814D1 DE 602004005814 T DE602004005814 T DE 602004005814T DE 602004005814 T DE602004005814 T DE 602004005814T DE 602004005814 D1 DE602004005814 D1 DE 602004005814D1
- Authority
- DE
- Germany
- Prior art keywords
- evilness
- infringement
- organization
- treating
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Dental Preparations (AREA)
Abstract
Methods are disclosed for the treatment of nausea and vomiting in a patient suffering therefrom comprising administering 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44007603P | 2003-01-13 | 2003-01-13 | |
US440076P | 2003-01-13 | ||
US49247803P | 2003-08-04 | 2003-08-04 | |
US492478P | 2003-08-04 | ||
PCT/US2004/000809 WO2004062624A2 (en) | 2003-01-13 | 2004-01-13 | Method of treating nausea, vomiting, retching or any combination thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE602004005814D1 true DE602004005814D1 (en) | 2007-05-24 |
DE602004005814T2 DE602004005814T2 (en) | 2008-01-10 |
Family
ID=32718144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004005814T Expired - Fee Related DE602004005814T2 (en) | 2003-01-13 | 2004-01-13 | PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOF |
Country Status (14)
Country | Link |
---|---|
US (3) | US20040147510A1 (en) |
EP (1) | EP1567163B1 (en) |
JP (1) | JP2006516977A (en) |
KR (1) | KR20050094843A (en) |
AT (1) | ATE359079T1 (en) |
AU (1) | AU2004204827B2 (en) |
BR (1) | BRPI0406748A (en) |
CA (1) | CA2512022A1 (en) |
DE (1) | DE602004005814T2 (en) |
ES (1) | ES2285407T3 (en) |
MX (1) | MXPA05007379A (en) |
NZ (1) | NZ541009A (en) |
PL (1) | PL378369A1 (en) |
WO (1) | WO2004062624A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
AU2003259373B2 (en) * | 2002-08-29 | 2006-03-09 | Dynogen Pharmaceuticals, Inc. | New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine |
EP1567163B1 (en) * | 2003-01-13 | 2007-04-11 | Dynogen Pharmaceuticals Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
AU2004204825B2 (en) * | 2003-01-13 | 2007-07-19 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
ATE365554T1 (en) * | 2003-04-04 | 2007-07-15 | Dynogen Pharmaceuticals Inc | METHOD OF TREATING LOWER URINARY TRACT DISEASES |
WO2005007600A2 (en) * | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
US20060100290A1 (en) * | 2003-07-28 | 2006-05-11 | Dunaway Leslie J | Treatment of allergic rhinitis and asthma |
US20050282879A1 (en) * | 2004-06-17 | 2005-12-22 | Foad Salehani | Methods and composition for treatment of migraine and symptoms thereof |
US20060194837A1 (en) * | 2004-12-17 | 2006-08-31 | Carruthers Nicholas I | Tetrahydroisoquinoline compounds |
US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
EP1983827A4 (en) * | 2006-02-01 | 2013-07-10 | Stuart L Weg | Use of antifungal compositions to treat upper gastrointestinal conditions |
WO2007120445A1 (en) * | 2006-03-31 | 2007-10-25 | Dynogen Pharmaceuticals, Inc. | SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES |
US20070259933A1 (en) * | 2006-05-04 | 2007-11-08 | Xenoport, Inc. | Compositions, dosage forms and methods of treating emesis |
WO2008038106A1 (en) * | 2006-09-27 | 2008-04-03 | Orchid Chemicals & Pharmaceuticals Limited | Venlafaxine extended release formulations |
PL2432467T3 (en) * | 2009-05-20 | 2018-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders |
WO2014184662A2 (en) | 2013-03-14 | 2014-11-20 | Redhill Biopharma Ltd. | Antiemetic extended release solid dosage forms |
CN106456611B (en) | 2014-03-11 | 2021-07-20 | 红山生物医药有限公司 | Ondansetron sustained release solid formulations for treating nausea, vomiting or diarrhea symptoms |
HRP20240453T1 (en) | 2016-04-14 | 2024-06-21 | Sensorion | (+)-azasetron for use in the treatment of ear disorders |
US20230266304A1 (en) * | 2020-07-15 | 2023-08-24 | St. Jude Children's Research Hospital, Inc. | Obese ferret model and methods of establishing and using the same |
WO2023164132A1 (en) * | 2022-02-25 | 2023-08-31 | Neuraxis, Inc. | Auricular nerve field stimulation device and methods for using the same |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US107244A (en) * | 1870-09-13 | Improved manner of treating- cod-liver and castor-oils | ||
US44450A (en) * | 1864-09-27 | Improvement in ore-crushers | ||
US48874A (en) * | 1865-07-18 | Improved extension door-knobs | ||
US36549A (en) * | 1862-09-23 | Improvement in caps | ||
US203055A (en) * | 1878-04-30 | Improvement in carpet-stretchers | ||
US254171A (en) * | 1882-02-28 | Car-axle box | ||
US254172A (en) * | 1882-02-28 | Half to laweence | ||
US36500A (en) * | 1862-09-23 | Joseph banks | ||
US4225407A (en) * | 1979-04-04 | 1980-09-30 | The Dow Chemical Company | Cathodic electrodeposition of polymers onto a conductive surface |
JPS60146891A (en) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | (2,3-d)thienopyrimidine derivative and its salt |
DE201165T1 (en) * | 1985-03-14 | 1989-04-20 | Beecham Group P.L.C., Brentford, Gb | MEDICINES FOR TREATING EMESIS, ANXIETAS AND "IRRITABLE BOWEL SYNDROME". |
GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
DE3885357T2 (en) * | 1987-06-29 | 1994-03-24 | Duphar Int Res | Fused indole derivatives. |
US5223511A (en) * | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
CA1304082C (en) | 1987-10-22 | 1992-06-23 | Tetsuya Tahara | Benzoxazine compounds and pharmaceutical use thereof |
US5530008A (en) * | 1989-04-21 | 1996-06-25 | Sandoz Ltd. | Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders |
US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
CA2112487C (en) * | 1991-06-26 | 2003-04-15 | James W. Young | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron |
JP2699794B2 (en) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | Thieno [3,2-b] pyridine derivative |
GB9214184D0 (en) | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
JPH0616557A (en) * | 1992-12-21 | 1994-01-25 | Mitsubishi Kasei Corp | Improver for cerebral cerebral function disorder |
GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
ES2156616T3 (en) * | 1995-07-28 | 2001-07-01 | Dainippon Pharmaceutical Co | (R) -5-BROMO-N- (1-ETIL-4-METILHEXAHYDRO-1H-1,4-DIAZEPAN-6-IL) -2-METOXI-6-METHYLAMINO-3-PYRIDINCARBOXAMIDE, PROCEDURE FOR PRODUCTION AND COMPOSITION MEDICINAL CONTAINING IT. |
AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
ATE250931T1 (en) * | 1996-02-15 | 2003-10-15 | Janssen Pharmaceutica Nv | USE OF 5-HT4 ANTAGONISTS TO OVERCOME GASTROINTESTINAL DAMAGE CAUSED BY SEROTONIN REUPtake INHIBITORS |
EP0975327B1 (en) * | 1997-04-18 | 2003-07-02 | Janssen Pharmaceutica N.V. | Use of 5ht3 antagonists for promoting intestinal lavage |
JPH10298078A (en) | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | Antianxiety medicine |
ES2128266B1 (en) | 1997-07-08 | 2000-01-16 | Vita Invest Sa | THIOPHENE AND BENZOTIOFEN DERIVATIVE COMPOUNDS AND RELEVANT USE AND COMPOSITION. |
DE19813661A1 (en) * | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Pharmaceutical preparations from Cilansetron stabilized against racemization |
DE19734444A1 (en) * | 1997-08-08 | 1999-02-11 | Basf Ag | 3-Substituted 3,4,5,7-tetrahydro-pyrrolo (3 ', 4': 4,5) thieno (2,3-d) pyrimidine derivatives, their preparation and use |
US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
US6117879A (en) * | 1997-09-16 | 2000-09-12 | Solvay Pharmaceuticals Gmbh | Methods of using moxonidine to inhibit nociceptive pain |
US6054461A (en) * | 1997-09-16 | 2000-04-25 | Solvay Pharmaceuticals Gmbh | Treatment of neuropathic pain |
GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
FR2781671A1 (en) | 1998-07-28 | 2000-02-04 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING SEROTONIN RECAPTURE INHIBITOR AND THERAPEUTIC USE THEREOF |
US6376550B1 (en) * | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
JP2002537245A (en) * | 1999-02-18 | 2002-11-05 | ノバルティス アクチエンゲゼルシャフト | Use of 5-HT3 receptor antagonist |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
AU5425400A (en) * | 1999-04-12 | 2000-11-14 | University Of Madras | A pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation |
DE19929197A1 (en) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermal systems for the delivery of 5-HT3 receptor antagonists and their use for antiemitic treatment |
PT1459750E (en) * | 1999-07-01 | 2005-08-31 | Pharmacia & Upjohn Co Llc | (S, S) - REBOXETINE FOR TREATING FIBROMYALGIA OR OTHER SOMATOFORM PERTURBACTIONS |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
TWI263496B (en) | 1999-12-10 | 2006-10-11 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
ES2188344B1 (en) | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | COMPOUNDS DERIVED FROM BENZOTIOPHENE, ITS PROCEDURE FOR OBTAINING AND USING THEMSELVES. |
US20020107244A1 (en) * | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
GB0112494D0 (en) | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
US6770655B2 (en) * | 2002-01-18 | 2004-08-03 | Aryx Therapeutics | 5-HT3 receptor antagonists and methods of use |
GB0202265D0 (en) * | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
AU2003225837B2 (en) | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
JP2005533829A (en) | 2002-07-10 | 2005-11-10 | アラクノーバ・セラピューティックス・リミテッド | 4- (2-Fluorophenyl) -6-methyl-2- (1-piperazinyl) thieno [2,3-D] pyrimidine in the treatment of functional bowel disease |
AU2003259373B2 (en) * | 2002-08-29 | 2006-03-09 | Dynogen Pharmaceuticals, Inc. | New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine |
AU2003290363A1 (en) | 2002-12-24 | 2004-07-22 | Amedis Pharmaceuticals Ltd. | Therapeutic use of selective noradrenaline reuptake inhibitors |
AU2004204825B2 (en) * | 2003-01-13 | 2007-07-19 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
EP1567163B1 (en) * | 2003-01-13 | 2007-04-11 | Dynogen Pharmaceuticals Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
-
2004
- 2004-01-13 EP EP04701830A patent/EP1567163B1/en not_active Expired - Lifetime
- 2004-01-13 DE DE602004005814T patent/DE602004005814T2/en not_active Expired - Fee Related
- 2004-01-13 AT AT04701830T patent/ATE359079T1/en not_active IP Right Cessation
- 2004-01-13 MX MXPA05007379A patent/MXPA05007379A/en active IP Right Grant
- 2004-01-13 WO PCT/US2004/000809 patent/WO2004062624A2/en active IP Right Grant
- 2004-01-13 PL PL378369A patent/PL378369A1/en not_active Application Discontinuation
- 2004-01-13 CA CA002512022A patent/CA2512022A1/en not_active Abandoned
- 2004-01-13 AU AU2004204827A patent/AU2004204827B2/en not_active Ceased
- 2004-01-13 ES ES04701830T patent/ES2285407T3/en not_active Expired - Lifetime
- 2004-01-13 JP JP2006500937A patent/JP2006516977A/en active Pending
- 2004-01-13 BR BR0406748-7A patent/BRPI0406748A/en not_active IP Right Cessation
- 2004-01-13 US US10/757,981 patent/US20040147510A1/en not_active Abandoned
- 2004-01-13 NZ NZ541009A patent/NZ541009A/en unknown
- 2004-01-13 KR KR1020057012925A patent/KR20050094843A/en not_active Application Discontinuation
- 2004-05-14 US US10/846,979 patent/US7094786B2/en not_active Expired - Fee Related
- 2004-05-14 US US10/846,978 patent/US20040254171A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004062624A3 (en) | 2005-04-07 |
EP1567163A4 (en) | 2006-01-18 |
US20040254171A1 (en) | 2004-12-16 |
US20040147510A1 (en) | 2004-07-29 |
AU2004204827B2 (en) | 2006-06-29 |
NZ541009A (en) | 2007-09-28 |
US7094786B2 (en) | 2006-08-22 |
AU2004204827A1 (en) | 2004-07-29 |
ES2285407T3 (en) | 2007-11-16 |
US20040254172A1 (en) | 2004-12-16 |
EP1567163B1 (en) | 2007-04-11 |
PL378369A1 (en) | 2006-04-03 |
ATE359079T1 (en) | 2007-05-15 |
WO2004062624A2 (en) | 2004-07-29 |
KR20050094843A (en) | 2005-09-28 |
MXPA05007379A (en) | 2006-02-10 |
CA2512022A1 (en) | 2004-07-29 |
BRPI0406748A (en) | 2005-12-20 |
JP2006516977A (en) | 2006-07-13 |
DE602004005814T2 (en) | 2008-01-10 |
EP1567163A2 (en) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004005814D1 (en) | PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOF | |
IL144643A0 (en) | Jak-3 inhibitors for treating allergic disorders | |
AP2006003621A0 (en) | Methods for treatment modification and management of pains using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoin-doleline | |
ATE380548T1 (en) | USE OF P53 INHIBITORS FOR THE TREATMENT OF ADVERSE SYMPTOMS OF CANCER THERAPY | |
DE60321929D1 (en) | PHARMACEUTICAL COMPOSITIONS WITH DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES | |
DE60142590D1 (en) | Use of botulinum toxin for the treatment of post-operative pain | |
MY169308A (en) | Treatment of tnf? related disorders | |
CY1107640T1 (en) | METHOD FOR CERTIFICATING FACTORS FOR DIABETES TREATMENT | |
ATE350030T1 (en) | NORDIHYDROGUAIARETIC ACID DERIVATIVES FOR THE TREATMENT OF TUMORS | |
ATE369861T1 (en) | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES | |
DE50114605D1 (en) | NO-THIEN-2-YL-VINEGAR DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MIGRAINE BZW. PAIN | |
ATE357912T1 (en) | INTRACORPORAL MEDICATIONS FOR HIGH-ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASES | |
DE60016047D1 (en) | DIHYDROBENZOPYRANE, DIHYDROBENZOTHIOPYRANE AND TETRAHYDROCHINOLINE FOR THE TREATMENT OF COX-2-DEPENDENT DISEASES | |
DE50313329D1 (en) | 1-PHENYL-2-DIMETHYLAMINOMETHYLCYCLOHEXANE COMPOUNDS FOR THE THERAPY OF DEPRESSIVE SYMPTOMATICS, PAIN AND INCONTINENCE | |
DE50100833D1 (en) | USE OF 2-METHYL-THIAZOLIDINE-2,4-DICARBONIC ACID AND / OR ITS PHYSIOLOGICALLY COMPATIBLE SALTS FOR PRODUCING A MEDICINE FOR TREATING CANCER DISEASES | |
ATE406171T1 (en) | APLIDINE FOR THE TREATMENT OF MULTIPLE MYELOMA | |
DE60141979D1 (en) | USE OF ENDOTHELIN ANTAGONISTS FOR THE TREATMENT OF BONE CANCER AND RELATED PAIN | |
ATE359808T1 (en) | USE OF SARP-1 TO TREAT AND/OR PREVENT SCLERODERMA | |
DK1244438T3 (en) | Use of beta-adrenoceptor antagonists in the manufacture of a medicament for the treatment of diseases of the outer retina | |
BR0312511A (en) | 4- (2-fluorophenyl) -6-methyl-2- (1-piperazinyl) thieno [2,3-d] pyrimidine in the treatment of functional bowel disorder | |
ATE262362T1 (en) | USE OF CYAMEMAZINE TO TREAT WITHDRAWING SYMPTOMS OF BENZODIAZEPINE TREATMENT | |
ATE314066T1 (en) | USE OF BUPRENORPHINE FOR THE TREATMENT OF URINARY INCONTINENCE | |
GB0112494D0 (en) | New therapeutic use | |
ATE460168T1 (en) | NON-RADIOACTIVE STRONTIUM AGENT FOR THE TREATMENT OF CANCER | |
GB0216027D0 (en) | New therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |